Department: Clinical Science and Services
Research Groups: CPCS (Research Programme)
Clinical Groups: Small Animal Soft Tissue Surgery
Floryne enjoys all areas of soft tissue surgery, although she has a particular interest in surgical oncology. Her translational and clinical investigations focus on the identification of new methods and strategies for improving the diagnosis, personalised treatment and prognostication of canine and human endocrine cancers.
Floryne Buishand graduated summa cum laude from The Faculty of Veterinary Medicine, Utrecht University in 2010 and subsequently completed a rotating internship there in Small Animal Medicine. During her internship she was able to obtain a stipend from The Netherlands Organisation for Health Research and Development, which enabled her to start her PhD studies alongside her clinical residency training in Small Animal Surgery of the European College of Veterinary Surgeons (ECVS). Her PhD studies focused on the identification of prognostic factors, druggable genes and cancer stem cells in canine and human insulinoma. After completing her PhD in 2016, she obtained a Rubicon Fellowship from The Netherlands Organisation for Scientific Research, which enabled her to perform postdoctoral research at The National Cancer Institute (NCI) at the National Institutes of Health, Bethesda, MD, USA. At NCI she studied genomic changes associated with endocrine and colorectal cancers with the ultimate goal of identifying novel diagnostic and prognostic markers, as well as novel therapeutic targets. In 2018 she moved to the UK to take on a position as Lecturer in Small Animal Surgery at the Royal (Dick) School of Veterinary Studies, University of Edinburgh. Subsequently in 2021, she started a Lectureship in Small Animal Soft Tissue Surgery at The Royal Veterinary College, University of London. Floryne is an RCVS and European recognised Specialist in Small Animal Surgery. Her main clinical and translational research interest is the identification of new methods and strategies for improving the diagnosis, personalised treatment and prognostication of canine and human endocrine cancers.
Publications in peer-reviewed journals
Buishand FO. Current trends in diagnosis, treatment and prognosis of canine insulinoma. Vet Sci 2022;9:540.
Davenport A, Thompson J-L, Cazzini P, Sangster C, Buishand FO. An incidental finding of numerous hypocellular nodules within a mandibular-sublingual gland complex sialocoele in a dog. Vet Rec Case Rep 2022;10:e451.
Capodanno Y, Buishand FO, Pang LY, Kirpensteijn J, Mol JA, Elders R, Argyle DJ. Transcriptomic analysis by RNA sequencing characterises malignant progression of canine insulinoma from normal tissue to metastatic disease. Sci Rep 2020;10:11581.
Buishand FO, Liu-Chittenden Y, Fan Y, Tirosh A, Gara SK, Patel D, Meerzaman D, Kebebew E. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. Surgery 2020;167:224-232.
Buishand FO, Vilaplana Grosso FR, Kirpensteijn J, Van Nimwegen SA. Utility of contrast-enhanced computed tomography in the evaluation of canine insulinoma location. Vet Q 2018;38:53-62.
Wangsa D, Braun R, Schiefer M, Gertz EM, Bronder D, Quitanilla I, Padilla-Nash HM, Torres I, Hunn C, Warner L, Buishand FO, Hu Y, Hirsch D, Gaiser T, Camps J, Schwartz R, Schäffer AA, Heselmeyer-Haddad K, Ried T. The evolution of single cell-derived colorectal cancer cell lines is dominated by the continued selection of tumor-specific genomic imbalances despite random chromosomal instability. Carcinogenesis 2018;39:993-1005.
Capodanno Y*, Buishand FO*, Pang LY, Kirpensteijn J, Mol JA, Argyle DJ. Inhibition of the Notch pathway enhances sensitivity of canine and human insulinoma cancer stem cells to 5-fluorouracil. Endocr Relat Cancer 2018;25:131-144. *Joint first authorship
Buishand FO, Cardin E, Hu Y, Ried T. Trichostatin A preferentially reverses the upregulation of gene-expression levels induced by gain of chromosome 7 in colorectal cancer cell lines. Genes Chromosomes Cancer 2018:37:35-41.
Shukla V, Rao M, Zhang H, Beers J, Wangsa D, Wangsa D, Buishand FO, Wang Y, Yu Z, Stevenson HS, Reardon ES, McLoughlin KC, Kaufman AS, Payabyan EC, Hong JA, Zhang M, Davis S, Edelman D, Chen G, Miettinen MM, Restifo NP, Ried T, Meltzer PA, Schrump DS. ASXL3 is a novel pluripotency factor in human respiratory epithelial cells and a potential therapeutic target in small cell lung cancer. Cancer Res 2017;77:6267-6281.
McNeil NE, Padilla-Nash HM, Buishand FO, Hue Y, Ried T. Novel mouse model recapitulates genome and transcriptome alterations in human colorectal carcinomas. Genes Chromosomes Cancer 2017;56:199-213.
Buishand FO, Arkesteijn GJ, Feenstra L, Oorsprong CW, Mestemaker M, Starke A, Speel EJ, Kirpensteijn J, Mol JA. Identification of CD90 as a putative cancer stem cell marker and therapeutic target in insulinomas. Stem Cells Dev 2016;25:826-35.
Buishand FO, Visser J, Kik M, Gröne A, Keesler RI, Briaire-de Bruijn IH, Kirpensteijn J. Evaluation of prognostic indicators using validated canine insulinoma tissue microarrays. Vet J 2014;201:57-63.
Buishand FO, Kirpensteijn J, Jaarsma AA, Speel EJ, Kik M, Mol JA. Gene expression profiling of primary canine insulinomas and their metastases. Vet J 2013;197:192-195.
Buishand FO, van Erp MG, Groenveld HA, Mol JA, Kik M, Robben JH, Kooistra HS, Kirpensteijn, J. Expression of insulin-like growth factor-1 by canine insulinomas and their metastases. Vet J 2012;191:334-340.
Wouters EG, Buishand FO, Kik M, Kirpensteijn J. Use of a bipolar vessel-sealing device in resection of canine insulinoma. J Small Anim Pract 2011;52:139–145.
Buishand FO, Kik M, Kirpensteijn J. Evaluation of clinico-pathological criteria and the Ki67 index as prognostic indicators in canine insulinoma. Vet J 2010;185:62-67.
Van Nimwegen SA, Buishand FO, Kirpensteijn J. Pancreas Surgery. In: Case B, Pievaroli A, Collivignarelli, editors. Laparoscopy and Thoracoscopy in the Dog and Cat 1st ed. [in press]
Buishand FO, Kirpensteijn J. Advances in canine and feline insulinoma. In: Monnet E, editor. Small Animal Soft Tissue Surgery 2nd ed. Ames: John Wiley & Sons; 2023.
Van Nimwegen SA, Buishand FO, Kirpensteijn J. Laparoscopic surgery of the pancreas. In: Fransson BA, Mayhew PD, editors. Small Animal Laparoscopy and Thoracoscopy 2nd ed. Hoboken: Wiley-Blackwell; 2021.
Buishand FO, Kirpensteijn J. The Pancreas. In: Williams JM, Niles JD, editors. BSAVA Manual of Canine and Feline Abdominal Surgery 2nd ed. Hoboken: Wiley-Blackwell; 2015.
Buishand FO, van Nimwegen SA, Kirpensteijn J. Laparoscopic surgery of the pancreas. In: Fransson BA, editor. Small Animal Laparoscopy and Thoracoscopy 1st ed. Hoboken: Wiley-Blackwell; 2015.
Buishand FO, Kirpensteijn J. Advances in canine and feline insulinoma. In: Monnet E, editor. Small Animal Soft Tissue Surgery 1st ed. Ames: John Wiley & Sons; 2012.
Floryne has various teaching roles including undergraduate clinical rotational teaching and Senior Clinical Training Scholar supervision. She is involved in lecturing and case based teaching teaching of the 3rd year BVetMed students in soft tissue surgery related subjects. Floryne also designed and tutors the CPD course 'Current concepts in small animal endocrine surgical oncology'.
Insulinomas in dogs are difficult to cure by surgery. We investigate which genes are crucial for survival of insulinoma cells, allowing us to design new treatments targeted at these genes. Insulinomas are the most common pancreatic neuroendocrine tumours in dogs and humans. Current treatment options are limited to surgery and palliative medical therapy. Survival is poor with a median of 4 [range 0-18] months and 14 [range 0-51] months for medically and surgically treated dogs, respectively. Hence, new, more precise treatments are needed to improve the clinical outcome for dogs and humans with malignant insulinomas.
Insulinomas are the most common tumours of the pancreas in dogs. This multi-institutional prospective study evaluates the effectiveness of the drug toceranib phosphate in the treatment of insulinomas in dogs. This is an observational multi-institutional prospective trial. Client preferences regarding control/treatment group allocation will be followed and enrolment will not be blinded or randomised.
Cancer remains a formidable challenge, affecting both our beloved companion animals and ourselves. The RVC Cancer Biobank takes centre stage as a crucial resource in the quest for biomedical advancements. By offering a standardised approach to biospecimen collection and archiving, our mission is to accelerate cancer research and drive the development of precision medicine. Through the power of linking cancer samples with comprehensive patient information, we can pave the way for more effective, targeted, and less toxic therapies.